FY2025 · ended Sep 30, 2025 · Revenue $829.45M, +23258.2% YoY · Filed Nov 25, 2025
Arrowhead Pharmaceuticals, Inc. (ARWR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Sep 30, 2025, it reported revenue of $829.4 million and a net loss of $1.6 million. Free cash flow was $156.9 million. As of Jun 30, 2026 it held $1.6 billion in cash and investments and $119.6 million in total debt.
Revenue (TTM)
$669.50M
+16.8% vs year-ago TTM
Net income (TTM)
$-319.95M
-115.6% vs year-ago TTM
Operating cash flow (TTM)
$-59.05M
-370.3% vs year-ago TTM
Free cash flow (TTM)
$-75.11M
-326.3% vs year-ago TTM
EPS (TTM)
$-2.29
-102.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
135.81M
+9.1% vs prior year
Net cash
$1.48B
as of Jun 30, 2026
Operating margin
-33.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARWR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Pasadena, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 879407
- Former names
- ARROWHEAD RESEARCH CORP (until Apr 6, 2016); INTERACTIVE GROUP INC (until Jan 9, 2004); INTERACTIVE INC (until Feb 13, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $829.4M | $3.6M | $240.7M | $243.2M | $138.3M |
| Operating income | $98.3M | -$601.1M | -$205.0M | -$178.5M | -$149.0M |
| Net income | -$1.6M | -$599.5M | -$205.3M | -$176.1M | -$140.8M |
| Diluted EPS | -$0.01 | -$5.00 | -$1.92 | -$1.67 | -$1.36 |
| Operating cash flow | $179.6M | -$462.9M | -$153.9M | -$136.1M | $171.3M |
| Free cash flow | $156.9M | -$604.3M | -$330.6M | -$188.9M | $147.7M |
| Total assets | $1.4B | $1.1B | $765.6M | $691.9M | $710.1M |
| Stockholders' equity | $466.1M | $185.4M | $271.3M | $398.5M | — |
| Cash and investments | $919.4M | $681.0M | $403.6M | $108.0M | $311.2M |
| Total debt | $111.4M | $117.4M | $115.2M | $81.6M | $25.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, New debt
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 16, 2026 | Jun 12, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
All 1001 Arrowhead Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.